biostudies-literatureXu JOverseas Expertise Introduction Project for Discipline InnovationNational Natural Science Foundation of ChinaShanghai Collaborative Innovation Program on Regenerative Medicine and Stem Cell ResearchShanghai Pujiang ProgramDouble First-Class Project23https://www.ebi.ac.uk/biostudies/studies/S-EPMC11040812biostudies-literatureUnknown17(1)<h4>Background</h4>The autologous anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy LCAR-B38M has been approved for the treatment of relapsed and refractory multiple myeloma in many countries across the world under the name ciltacabtagene autoleucel. LEGEND-2 was the first-in-human trial of LCAR-B38M and yielded deep and durable therapeutic responses. Here, we reported the outcomes in LEGEND-2 after a minimal 5-year follow-up.<h4>Methods</h4>Participants received an average dose of 0.5 × 10⁶ cells/kg LCAR-B38M in split or single unfractionated infusions after cyclophosphamide-based lymphodepletion therapy. Investigator-assessed response, survival, safety and pharmacokinetics were evaluated.<h4>Results</h4>Seventy-four participants enrolled and Journal of hematology & oncologyLong-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial.PMC1104081282230006B17029820702272019CXJQ0122PJ1409800WF51016260282370201Yang SSYu SHChen SJHou JWang BYChen ZMi JQZhao WHLiu RChen LJHe ALXu JfalseLong-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial.<h4>Background</h4>The autologous anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy LCAR-B38M has been approved for the treatment of relapsed and refractory multiple myeloma in many countries across the world under the name ciltacabtagene autoleucel. LEGEND-2 was the first-in-human trial of LCAR-B38M and yielded deep and durable therapeutic responses. Here, we reported the outcomes in LEGEND-2 after a minimal 5-year follow-up.<h4>Methods</h4>Participants received an average dose of 0.5 × 10⁶ cells/kg LCAR-B38M in split or single unfractionated infusions after cyclophosphamide-based lymphodepletion therapy. Investigator-assessed response, survival, safety and pharmacokinetics were evaluated.<h4>Results</h4>Seventy-four participants enrolled and 2024-01-01T00:00:00Z2024 Apr2026-06-01T09:17:11.343Z2026-04-08T11:05:14.169ZS-EPMC110408123865904610.1186/s13045-024-01530-z